Dietary effect of apple cider vinegar and propionic acid on immune related transcriptional responses and growth performance in white shrimp, Litopenaeus vannamei.

This experiment was conducted to study the effect of various levels of ACV® and Propionic acid (PA) on expression of immune related genes and growth performance in white shrimp (Litopenaeus vannamei). Three hundred and seventy-five shrimps with an average initial weight of 10.2 ± 0.04 g were collected and acclimatized for two weeks. Five experimental diets including control diet, 0.5% PA diet and 1%, 2% and 4% ACV® diets were applied to feed the shrimps. They were fed 4 times a day with 2.5% of body weight. After 60 days of culture, shrimps fed with ACV® and PA diets showed no significant difference in growth performance. Expression of prophenoloxidase (proPo), lysozyme (Lys), penaeidin-3a (Pen-3a) and Crustin (Cru) genes were determined from hepatopancreas, using the real-time PCR after 15, 30 and 60 days. Expression of Lys and proPo genes was significantly up regulated in shrimps fed with ACV® and PA diets compared to the control group after 30 and 60 days of treatment. After 15 days, Pen-3a gene expression was significantly higher in PA group compared to the control group. Also, shrimps fed with 1% and 4% ACV® and PA diets showed significantly increased expression of Pen-3a after 30 days. In contrast, expression of Cru was significantly down regulated in response to ACV® diets, but, Cru expression in treated shrimps with PA diet was greater than the control group after 30 and 60 days. Overall, the results provided evidence that ACV® could be used as a natural immunostimulant for shrimps in order to adjust and enhance expression of the immune related genes.

Advances in the treatment of lupus nephritis.

Systemic lupus erythematosus (SLE) is an autoimmune disease that leads to the formation and deposition of immune complexes throughout the body, which are pathogenic for the disease. Different forms of glomerulonephritis can occur in patients with SLE and can contribute significantly to the associated morbidity and, ultimately, mortality from the disease. Over the past two decades, there have been significant strides in our understanding of the disease and in treatments that attempt to control the formation and deposition of anti-DNA auto-antibodies and immune complexes, as well as the subsequent inflammatory cascade mediated through various cellular and humoral pathways leading to progressive renal damage and end-stage renal disease. In this chapter, we review the current understanding of the pathogenesis and treatment of lupus nephritis in its various stages and discuss the experimental and human data regarding some of the potential newer forms of therapy. We discuss data regarding the use of steroids, azathioprine, cyclophosphamide, cyclosporine A, mycophenolate mofetil, gammaglobulin, plasmapheresis, LJP 394, flaxseed oil, bindarit, anti-CD40 ligand, and CTLA4Ig.